Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Sells 1,000 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 1,000 shares of the company’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $19.97, for a total value of $19,970.00. Following the completion of the transaction, the chief financial officer now directly owns 73,849 shares in the company, valued at approximately $1,474,764.53. The trade was a 1.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kory James Wentworth also recently made the following trade(s):

• On Monday, December 2nd, Kory James Wentworth sold 5,000 shares of Entrada Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $100,000.00.
• On Monday, November 11th, Kory James Wentworth sold 8,637 shares of Entrada Therapeutics stock. The stock was sold at an average price of $19.98, for a total transaction of $172,567.26.
• On Monday, September 9th, Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock. The stock was sold at an average price of $14.97, for a total transaction of $47,829.15.

Entrada Therapeutics Price Performance

Shares of TRDA traded down $0.15 during trading hours on Tuesday, hitting $20.17. The stock had a trading volume of 161,090 shares, compared to its average volume of 107,529. The stock has a market capitalization of $754.76 million, a price-to-earnings ratio of 12.69 and a beta of -0.18. The company’s fifty day moving average is $17.70 and its two-hundred day moving average is $16.34. Entrada Therapeutics, Inc. has a 52 week low of $11.35 and a 52 week high of $20.50.

Institutional Trading of Entrada Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TRDA. Janus Henderson Group PLC grew its stake in shares of Entrada Therapeutics by 10.5% during the third quarter. Janus Henderson Group PLC now owns 1,711,459 shares of the company’s stock worth $27,358,000 after purchasing an additional 161,962 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Entrada Therapeutics by 132.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company’s stock worth $2,215,000 after acquiring an additional 78,953 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new position in Entrada Therapeutics during the third quarter valued at approximately $1,109,000. Jacobs Levy Equity Management Inc. raised its holdings in Entrada Therapeutics by 50.3% in the third quarter. Jacobs Levy Equity Management Inc. now owns 201,803 shares of the company’s stock worth $3,225,000 after purchasing an additional 67,559 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Entrada Therapeutics by 8.8% in the 3rd quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock valued at $9,214,000 after buying an additional 46,512 shares during the period. 86.39% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

TRDA has been the subject of a number of analyst reports. HC Wainwright boosted their price target on Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Oppenheimer boosted their target price on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, November 6th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.